ROYAL BANK OF CANADA - TAKEDA PHARMACEUTICAL CO LTD ownership

TAKEDA PHARMACEUTICAL CO LTD's ticker is TAK and the CUSIP is 874060205. A total of 294 filers reported holding TAKEDA PHARMACEUTICAL CO LTD in Q1 2023. The put-call ratio across all filers is 0.29 and the average weighting 0.1%.

Quarter-by-quarter ownership
ROYAL BANK OF CANADA ownership history of TAKEDA PHARMACEUTICAL CO LTD
ValueSharesWeighting
Q3 2023$6,198,000
-71.7%
400,652
-71.2%
0.00%
-66.7%
Q2 2023$21,884,000
+216.6%
1,393,045
+232.1%
0.01%
+200.0%
Q1 2023$6,912,000
+17.3%
419,404
+11.0%
0.00%0.0%
Q4 2022$5,895,000
+21.5%
377,848
+1.0%
0.00%0.0%
Q3 2022$4,853,000
-6.2%
374,214
+1.5%
0.00%0.0%
Q2 2022$5,175,000
-7.5%
368,640
-5.6%
0.00%
+100.0%
Q1 2022$5,592,000
+14.6%
390,560
+9.1%
0.00%0.0%
Q4 2021$4,879,000
-23.7%
358,033
-8.3%
0.00%
-50.0%
Q3 2021$6,393,000
-5.7%
390,264
-3.2%
0.00%0.0%
Q2 2021$6,783,000
-7.8%
403,066
+0.1%
0.00%0.0%
Q1 2021$7,354,000
+25.1%
402,750
+24.7%
0.00%0.0%
Q4 2020$5,880,000
-65.8%
322,996
-66.5%
0.00%
-66.7%
Q3 2020$17,183,000
+1.2%
963,115
+1.7%
0.01%0.0%
Q2 2020$16,986,000
+6.2%
947,343
-10.1%
0.01%
-14.3%
Q1 2020$15,990,000
-10.9%
1,053,224
+15.8%
0.01%
+16.7%
Q4 2019$17,941,000
+12.2%
909,344
-2.1%
0.01%0.0%
Q3 2019$15,985,000
-4.2%
929,251
-1.4%
0.01%0.0%
Q2 2019$16,685,000
+583.3%
942,636
+686.5%
0.01%
+500.0%
Q1 2019$2,442,000
+529.4%
119,856
+420.1%
0.00%
Q4 2018$388,00023,0470.00%
Other shareholders
TAKEDA PHARMACEUTICAL CO LTD shareholders Q1 2023
NameSharesValueWeighting ↓
Blackcrane Capital, LLC 30,201$3,149,00019.29%
MANAGED ASSET PORTFOLIOS, LLC 1,399,878$20,046,0002.75%
Clean Yield Group 251,220$3,597,0001.27%
Mondrian Investment Partners LTD 4,319,715$60,476,0001.24%
Sippican Capital Advisors 80,490$1,153,0000.96%
TFG Asset Management GP Ltd 1,275,656$18,268,0000.83%
Lumbard & Kellner, LLC 132,516$1,898,0000.74%
BRANDES INVESTMENT PARTNERS, LP 2,109,846$30,213,0000.65%
CAUSEWAY CAPITAL MANAGEMENT LLC 1,601,046$22,927,0000.55%
Ridgewood Investments LLC 33,378$478,0000.31%
View complete list of TAKEDA PHARMACEUTICAL CO LTD shareholders